Abstract Double-hit lymphoma (DHL) is a high-grade B-cell lymphoma with MYC and BCL-2/BCL-6 rearrangement, which is a invasive disease with a poor prognosis. FISH is the most important diagnostic method. There is no standard protocol for this disease yet. New therapeutic approaches including targeted therapy，checkpoint inhibitors and chimeric antigen receptor T-cell therapy are changing the paradigm of treatment for DHL. This review summarizes new developments in diagnosis and treatment of double-hit lymphoma.
题目: 双打击淋巴瘤诊断和治疗最新研究进展.
摘要: 双打击淋巴瘤（double hit lymphoma DHL）是具有MYC和BCL-2/BCL-6基因重排的高级别B细胞淋巴瘤。该病患者的预后较差。要明确诊断DHL须完善FISH检查，而该检查在临床上尚未广泛开展，造成了一定量的漏诊。目前DHL仍以化疗为主，大多数患者疗效不佳，国际上对DHL治疗积极进行了探索，免疫疗法和相关途径的靶向药物治疗为DHL的治疗提供了新方向。本文就近年来DHL 的诊断和治疗的最新研究进展作一综述。.